ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2102

The Difference between International Criteria for BD (ICBD) and the BD Criteria of International Study Group (ISG) in Our Behcet’s Disease (BD) Patients Who Fulfilled Japanese BD Criteria

Tsuyoshi Kobashigawa, Yuki Nanke, Hisashi Yamanaka and Shigeru Kotake, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Behcet's syndrome, classification criteria and diagnostic criteria

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: In Japan, we have a criteria for BD since 1988. (International Journal of Tissue Reactions. 1988: 10; 59-65.) In Japanese patients diagnosed according to this Japanese BD criteria, the recent number of patients with the ocular lesions decreased compared with those with of the passed time; however, those the intestinal lesions increased. Moreover, a new international criteria for Behcet’s disease (ICBD) was proposed in 2006. (Clinical and Experimental Rheumatology. 2006: 24; S13, S14-15.) In ICBD the intestinal lesions were excluded as well as the criteria of international study group (ISG) in 1990 (Lancet. 1990: 335; 1078-80.).The purposes of this study are to analyze the clinical features of BD with comparison among four 5-year-patient groups, and to search which criteria was useful for Japanese BD patients between ISG and ICBD.

Methods: We enrolled our 264 (67.2%) BD patients out of 393. We diagnosed the patients having BD with Japanese BD criteria. We divided our patients to four groups with ones arriving period of 5 years: 49 BD patients were arrived at our clinic and started following until 2000, 70 patients from 2001 to 2005, 77 from 2006 to 2010, and 69 from 2011 to 2015, and compared symptoms of BD among four groups. We then analyzed the escape rate of our Japanese BD patients when we evaluated between ISG and ICBD. Moreover, we compared each rate, which criteria will be more usefull for Japanese BD patients comparing escape rate with chi square test.

Results: The characteristics of our 264 BD patients were as described below: 264 recurrent oral aphtous ulcers (100.0%), 206 genital ulcers (78.0%), 103 ocular manifestations (39.0%), 246 skin manifestations (93.2%), 161 arthritis (61.0%), 7 pathergy tests (2.7%), 71 intestinal lesions (26.9%), 23 neural lesions (8.7%), 22 vascular (8.3%), 11 epidemititis (4.20%), 75 male (28.4%), 136 HLA-B5 (51.5%), 86 HLA-B51 (32.6%), 16 HLA-A26 (6.1%). There was no significant differentiations among periods. The escape rate of our BD patients using ISG was 12.9% (n=34) and that using ICBD was 23.4% (n=15), and statistical analyses showed that ICBD may be useful criteria for Japanese BD patient (chi’s P<0.005: p=0.0044).

Conclusion: The clinical features of our BD patients did not change among four 5-year periods. In our BD patients diagnosed with Japanese BD criteria, the diagnosing criteria for BD called ICBD was better item than ISG.


Disclosure: T. Kobashigawa, None; Y. Nanke, None; H. Yamanaka, MSD, Astellas, AbbVie, BMS, Kaken, UCB, Ono, Ayumi, Eisai, Daiichi-Sankyo, Takeda, Tanabe-Mitsubishi, Chugai, Teijin, Torii, Nipponshinyaku, and Pfizer, 2,Pfizer, YL biologics, Takeda, Teijin, BMS, Nipponkayaku, Chugai, Tanabe-Mitsubishi, Daiichi-Sankyo and Astellas, 5; S. Kotake, None.

To cite this abstract in AMA style:

Kobashigawa T, Nanke Y, Yamanaka H, Kotake S. The Difference between International Criteria for BD (ICBD) and the BD Criteria of International Study Group (ISG) in Our Behcet’s Disease (BD) Patients Who Fulfilled Japanese BD Criteria [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-difference-between-international-criteria-for-bd-icbd-and-the-bd-criteria-of-international-study-group-isg-in-our-behcets-disease-bd-patients-who-fulfilled-japanese-bd-criteria/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-difference-between-international-criteria-for-bd-icbd-and-the-bd-criteria-of-international-study-group-isg-in-our-behcets-disease-bd-patients-who-fulfilled-japanese-bd-criteria/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology